Christoph Mann
Marburg An Der Lahn, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 21, 2026
Laboratory diagnostic in multiple myeloma: Quantification of daratumumab blood levels using isoelectric focusing.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: August 06, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma.
Journal: Blood cancer journal
Published: July 02, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial.
Journal: Cardio-oncology (London, England)
Published: April 06, 2025
Automated Detection of Focal Bone Marrow Lesions From MRI: A Multi-center Feasibility Study in Patients with Monoclonal Plasma Cell Disorders.
Journal: Academic radiology
Published: March 21, 2025
Beyond the Hydrashift assay: the utility of isoelectric focusing for therapeutic antibody and paraprotein detection.
Journal: Clinical chemistry and laboratory medicine
Published: March 20, 2025
Presentation of extramedullary myeloma manifestations on B-mode (B-US) and contrast-enhanced ultrasound (CEUS).
Journal: Journal of ultrasonography
Published: January 14, 2025
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.
Journal: Future oncology (London, England)
Published: September 30, 2024
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.
Journal: Leukemia
Published: December 01, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 27, 2023
Last Updated: 09/26/2026